A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

C. Yurdaydin; R. Idilman; O. Keskin; C. Kalkan; F. M. Karakaya; A. Caliskan; E. Yurdcu; S. C. Karatayli; M. A. Bozdayi; K. Kazempour; C. Koh; T. Heller; J. S. Glenn

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

C. Yurdaydin
, R. Idilman
, O. Keskin
, C. Kalkan
, F. M. Karakaya
, A. Caliskan
, E. Yurdcu
, S. C. Karatayli
, M. A. Bozdayi
, K. Kazempour
, C. Koh
, T. Heller
, J. S. Glenn

İç Hastalıkları Anabilim Dalı

Araştırma sonucu: Dergiye katkı › Toplantı Özeti › bilirkişi

Orijinal dil	İngilizce
Sayfa (başlangıç-bitiş)	10-10
Sayfa sayısı	1
Dergi	Journal of Viral Hepatitis
Hacim	25
Yayın durumu	Yayınlandı - Haz 2018

BM SKH

Bu sonuç, aşağıdaki Sürdürülebilir Kalkınma Hedefine/Hedeflerine katkıda bulunur

SKH 3 Sağlık ve Kaliteli Yaşam

Diger dosyalar ve linkler

View record in Web of Science

Bundan alıntı yap

Yurdaydin, C., Idilman, R., Keskin, O., Kalkan, C., Karakaya, F. M., Caliskan, A., Yurdcu, E., Karatayli, S. C., Bozdayi, M. A., Kazempour, K., Koh, C., Heller, T., & Glenn, J. S. (2018). A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay. Journal of Viral Hepatitis, 25, 10-10.

@article{56ccf9da36ac43d9aab6e012d322678b,

title = "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene{\textregistered} real-time qPCR HDV RNA assay",

author = "C. Yurdaydin and R. Idilman and O. Keskin and C. Kalkan and Karakaya, \{F. M.\} and A. Caliskan and E. Yurdcu and Karatayli, \{S. C.\} and Bozdayi, \{M. A.\} and K. Kazempour and C. Koh and T. Heller and Glenn, \{J. S.\}",

year = "2018",

month = jun,

language = "English",

volume = "25",

pages = "10--10",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

}

Yurdaydin, C, Idilman, R, Keskin, O, Kalkan, C, Karakaya, FM, Caliskan, A, Yurdcu, E, Karatayli, SC, Bozdayi, MA, Kazempour, K, Koh, C, Heller, T & Glenn, JS 2018, 'A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay', Journal of Viral Hepatitis, hac. 25, pp. 10-10.

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay. / Yurdaydin, C.; Idilman, R.; Keskin, O. et al.
In: Journal of Viral Hepatitis, Hac. 25, 06.2018, p. 10-10.

Araştırma sonucu: Dergiye katkı › Toplantı Özeti › bilirkişi

TY - JOUR

T1 - A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

AU - Yurdaydin, C.

AU - Idilman, R.

AU - Keskin, O.

AU - Kalkan, C.

AU - Karakaya, F. M.

AU - Caliskan, A.

AU - Yurdcu, E.

AU - Karatayli, S. C.

AU - Bozdayi, M. A.

AU - Kazempour, K.

AU - Koh, C.

AU - Heller, T.

AU - Glenn, J. S.

PY - 2018/6

Y1 - 2018/6

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000435101000010&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 1352-0504

VL - 25

SP - 10

EP - 10

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

ER -